Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Alnylam Pharmaceuticals, Inc. operates as an early-stage therapeutics company. The Company discovers and develops drug and medicines for the treatment of human disease. Alnylam Pharmaceuticals serves health care sectors in the United States and the United Kingdom.
Website: alnylam.com


  • Good financial results growth rate 74.4% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (54.4%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 0.5% (LTM)
  • Share price is 152.1% higher than minimum and 26.4% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders sold company shares on $12.5 mln (-0.026% of cap.)

Key Financials (Download financials)

Ticker: ALNY
Share price, USD:  (0.0%)361.35
year average price 359.76  


year start price 256.45 2025-02-14

min close price 224.32 2025-04-08

max close price 491.22 2025-10-20

current price 361.35 2026-02-13
Common stocks: 120 848 523

Dividend Yield:  0.0%
EV / Sales: 9.4x
Margin (EBITDA LTM / Revenue): -3.2%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 43 669
Net Debt ($m): -1 387
EV (Enterprise Value): 42 282
EBITDA LTM (млн $): -144
Price to Book: 186.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-28fool.com

Should You Buy Alnylam Pharmaceuticals Before Feb. 12?

2025-12-07fool.com

Is Alnylam Pharmaceuticals a Millionaire Maker?

2025-11-30seekingalpha.com

American Century Ultra Fund Q3 2025 Contributors/Detractors And Notable Trades

2025-11-20reuters.com

UK's drug-cost watchdog recommends Alnylam's heart disease drug

2025-11-19seekingalpha.com

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies London Healthcare Conference 2025 Transcript

2025-11-18zacks.com

Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?

2025-11-08businesswire.com

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

2025-10-31zacks.com

ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales

2025-10-30seekingalpha.com

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2025 Earnings Call Transcript

2025-10-30zacks.com

Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-03 2025-07-31 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-10-27
acceptedDate 2025-10-03 16:15:23 2025-07-31 08:11:22 2025-02-13 08:31:57 2024-10-31 08:22:09 2024-08-01 08:22:58 2024-05-02 08:21:02 2024-02-15 16:23:12 2023-11-02 08:22:13 2023-08-03 08:18:45 2023-05-04 08:22:22 2023-02-23 08:19:23 2022-10-27 08:15:37 2022-02-10 08:22:31 2021-02-11 16:13:06
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 1 249M 774M 2 248M 501M 660M 494M 1 828M 751M 319M 319M 1 037M 264M 844M 493M
costOfRevenue 197M 143M 323M 86M 69M 66M 310M 84M 85M 55M 169M 41M 140M 78M
grossProfit 1 052M 631M 1 925M 415M 591M 428M 1 518M 666M 233M 264M 869M 223M 704M 415M
grossProfitRatio 0.842 0.815 0.829 0.896 0.867 0.888 0.732 0.828 0.844
researchAndDevelopmentExpenses 359M 324M 1 126M 271M 294M 261M 1 004M 253M 249M 231M 883M 245M 792M 655M
generalAndAdministrativeExpenses 322M 323M 976M 221M 248M 211M 796M 199M 215M 184M 771M 236M 621M 588M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 322M 323M 976M 221M 248M 211M 796M 199M 215M 184M 771M 236M 621M 588M
otherExpenses 3M 0 0 0 1M -6M 0 -58M -35M -12M 0 0 -2M 0
operatingExpenses 684M 647M 2 102M 492M 543M 472M 1 800M 452M 463M 414M 1 654M 481M 1 413M 1 243M
costAndExpenses 881M 790M 2 425M 578M 611M 538M 2 110M 537M 549M 469M 1 822M 522M 1 553M 1 321M
interestIncome 29M 27M 122M 32M 29M 30M 96M 25M 21M 19M 25M 8M 2M 12M
interestExpense 44M 40M 142M 34M 33M 35M 121M 31M 30M 29M 156M 41M 143M 84M
depreciationAndAmortization 14M 14M 57M 14M 15M 14M 54M -32M 23M 6M 44M 23M 48M 35M
ebitda 297M 19M -179M -60M 37M -30M -258M 182M -244M -143M -927M -235M -662M -736M
ebitdaratio 0.238 0.024 -0.12 0.096 -0.061 0.242 -0.766 -0.449 -0.888
operatingIncome 368M -16M -177M -77M 49M -43M -282M 214M -230M -150M -785M -258M -709M -828M
operatingIncomeRatio 0.295 -0.021 -0.154 0.074 -0.088 0.285 -0.721 -0.469 -0.976
totalOtherIncomeExpensesNet -129M -19M -200M -32M -60M -20M -151M -58M -35M -23M -342M -148M -143M -27M
incomeBeforeTax 239M -35M -377M -109M -11M -64M -434M 151M -274M -172M -1 127M -406M -852M -856M
incomeBeforeTaxRatio 0.191 -0.046 -0.217 -0.017 -0.129 0.201 -0.86 -0.54 -1.536
incomeTaxExpense -12M 31M -99M 3M 6M 2M 7M 3M 2M 2M 4M -23 000 680 000 3M
netIncome 251M -66M -278M -112M -17M -66M -440M 148M -276M -174M -1 131M -406M -853M -858M
netIncomeRatio 0.201 -0.086 -0.223 -0.026 -0.133 0.197 -0.866 -0.545 -1.536
eps 1.91 -0.51 -2.18 -0.87 -0.13 -0.52 -3.52 1.18 -2.21 -1.4 -9.3 -3.32 -7.2 -7.46
epsdiluted 1.84 -0.51 -0.87 -0.13 -0.52 1.15 -2.21 -1.4 -3.32
weightedAverageShsOut 131M 130M 128M 129M 127M 126M 125M 125M 125M 124M 122M 122M 118M 115M
weightedAverageShsOutDil 137M 130M 128M 129M 127M 126M 125M 131M 125M 124M 122M 122M 118M 115M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-23 2022-02-10 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -20M -26M -131M -141M -73M
ebit -236M -312M -971M -709M -771M
nonOperatingIncomeExcludingInterest 59M 30M 186M 471 000 -57M
netIncomeFromContinuingOperations -278M -440M -1 131M -853M -858M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -278M -440M -1 131M -853M -858M
epsDiluted -2.18 -3.52 -9.3 -7.2 -7.46

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-03 2025-07-31 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-10-27
acceptedDate 2025-10-03 16:15:23 2025-07-31 08:11:22 2025-02-13 08:31:57 2024-10-31 08:22:09 2024-08-01 08:22:58 2024-05-02 08:21:02 2024-02-15 16:23:12 2023-11-02 08:22:13 2023-08-03 08:18:45 2023-05-04 08:22:22 2023-02-23 08:19:23 2022-10-27 08:15:37 2022-02-10 08:22:31 2021-02-11 16:13:06
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 1 490M 1 114M 966M 1 100M 968M 682M 813M 1 033M 658M 672M 866M 1 073M 820M 497M
shortTermInvestments 1 234M 1 744M 1 728M 1 672M 1 656M 1 689M 1 627M 1 373M 1 400M 1 398M 1 326M 1 192M 1 616M 1 378M
cashAndShortTermInvestments 2 725M 2 858M 2 695M 2 772M 2 625M 2 371M 2 439M 2 406M 2 058M 2 071M 2 192M 2 265M 2 436M 1 874M
netReceivables 965M 567M 405M 354M 309M 321M 328M 325M 221M 219M 238M 185M 199M 602M
inventory 75M 72M 79M 76M 84M 94M 89M 96M 100M 132M 129M 115M 86M 75M
otherCurrentAssets 188M 147M 117M 154M 155M 202M 126M 158M 145M 119M 133M 126M 0 0
totalCurrentAssets 3 953M 3 644M 3 295M 3 355M 3 173M 2 989M 2 983M 2 985M 2 524M 2 541M 2 692M 2 691M 2 809M 2 615M
propertyPlantEquipmentNet 693M 692M 694M 703M 715M 719M 726M 729M 736M 738M 739M 734M 734M 707M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 54M 0 0 0 52M 52M 0 -10M -27M -26M 0 0 0 0
taxAssets 99M 104M 117M 0 0 0 10M 0 0 0 0 0 0 0
otherNonCurrentAssets 53M 126M 134M 146M 69M 65M 111M 135M 169M 139M 115M 111M 101M 86M
totalNonCurrentAssets 899M 922M 945M 850M 837M 836M 847M 854M 878M 851M 854M 844M 835M 792M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 4 852M 4 566M 4 240M 4 205M 4 010M 3 824M 3 830M 3 839M 3 402M 3 392M 3 546M 3 535M 3 643M 3 407M
accountPayables 118M 102M 88M 71M 74M 78M 56M 74M 60M 62M 98M 41M 73M 52M
shortTermDebt 160M 144M 113M 42M 104M 88M 0 42M 42M 43M 0 42M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 3M 15M 55M 71M 69M 77M 103M 77M 35M 36M 42M 144M 149M 127M
otherCurrentLiabilities 1 275M 1 040M 214M 1 037M 809M 699M 177M 757M 632M 532M 171M 546M 131M 111M
totalCurrentLiabilities 1 555M 1 301M 1 186M 1 221M 1 055M 942M 968M 950M 769M 673M 768M 773M 696M 585M
longTermDebt 2 613M 2 596M 2 359M 1 260M 2 605M 2 359M 1 021M 1 268M 1 272M 1 277M 1 017M 1 282M 676M 191M
deferredRevenueNonCurrent 0 0 0 1M 2M 186M 188M 196M 213M 191M 194M 133M 152M 225M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 239M 238M 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 449M 418M 398M 1 691M 350M 320M 1 631M 1 592M 1 556M 1 509M 1 465M 2 604M 1 250M 1 096M
totalNonCurrentLiabilities 3 062M 3 015M 2 987M 2 952M 2 957M 3 102M 3 083M 3 055M 3 041M 2 978M 2 937M 2 830M 2 359M 1 806M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 223M 271M 271M 278M 281M 238M 285M 289M 295M 302M 303M 308M 322M 330M
totalLiabilities 4 618M 4 315M 4 173M 4 173M 4 013M 4 044M 4 051M 4 005M 3 811M 3 651M 3 705M 3 603M 3 055M 2 391M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
retainedEarnings -7 160M -7 412M -7 288M -7 204M -7 092M -7 076M -7 010M -6 872M -7 019M -6 743M -6 569M -6 362M -5 438M -4 585M
accumulatedOtherComprehensiveIncomeLoss -22M -30M -35M -25M -35M -27M -23M -32M -37M -39M -45M -44M -33M -44M
othertotalStockholdersEquity 7 415M 7 691M 7 260M 7 123M 6 882M 6 737M 6 647M 6 522M 6 337M
totalStockholdersEquity 234M 251M 67M 32M -3M -219M -221M -166M -408M -259M -158M -68M 588M 1 016M
totalEquity 234M 251M 67M 32M -3M -219M -221M -166M -408M -259M -158M -68M 588M 1 016M
totalLiabilitiesAndStockholdersEquity 4 852M 4 566M 4 205M 4 010M 3 824M 3 839M 3 402M 3 392M 3 535M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 4 852M 4 566M 4 240M 4 205M 4 010M 3 824M 3 830M 3 839M 3 402M 3 392M 3 546M 3 535M 3 643M 3 407M
totalInvestments 1 288M 1 744M 1 728M 1 672M 1 708M 1 742M 1 627M 1 363M 1 372M 1 373M 1 326M 1 192M 1 616M 1 378M
totalDebt 2 773M 2 740M 2 743M 1 302M 2 708M 2 684M 1 305M 1 309M 1 314M 1 320M 1 320M 1 324M 998M 521M
netDebt 1 283M 1 626M 1 777M 202M 1 740M 2 002M 493M 276M 657M 648M 454M 251M 178M 25M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-23 2022-02-10 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 405M 328M 238M 199M 102M
otherReceivables 0 0 0 0 500M
prepaids 0 0 0 88M 63M
totalPayables 88M 56M 98M 73M 52M
otherPayables 0 0 0 0 0
accruedExpenses 673M 591M 415M 302M 258M
capitalLeaseObligationsCurrent 42M 42M 42M 41M 37M
capitalLeaseObligationsNonCurrent 230M 243M 261M 281M 293M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 7 388M 6 811M 6 455M 6 058M 5 644M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-03 2025-07-31 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-10-27
acceptedDate 2025-10-03 16:15:23 2025-07-31 08:11:22 2025-02-13 08:31:57 2024-10-31 08:22:09 2024-08-01 08:22:58 2024-05-02 08:21:02 2024-02-15 16:23:12 2023-11-02 08:22:13 2023-08-03 08:18:45 2023-05-04 08:22:22 2023-02-23 08:19:23 2022-10-27 08:15:37 2022-02-10 08:22:31 2021-02-11 16:13:06
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 251M -66M -278M -112M -17M -66M -440M 148M -276M -174M -1 131M -406M -853M -858M
depreciationAndAmortization 14M 14M 57M 49M 15M 14M 97M 24M 23M 26M 86M 21M 90M 74M
deferredIncomeTax 6M 10M -107M 0 0 0 0 39M 29M 0 0 0 -56M -54M
stockBasedCompensation 108M 112M 272M 46M 89M 45M 222M 64M 76M 40M 231M 128M 166M 140M
changeInWorkingCapital -205M 50M -214M 31M -49M -121M 11M 26M 65M -86M -36M 5M -163M -13M
accountsReceivables -400M -137M -87M -37M 10M 410 000 -88M -108M -3M 19M -46M -38M -102M -56M
inventory 5M 11M 14M 6M 7M 22 000 18M 5M 2M -403 000 -34M -8M -26M -35M
accountsPayables 224M 182M 91M 84M 74M -5M 81M 119M 83M -82M 192M 70M 88M 117M
otherWorkingCapital -33M -6M -232M -22M -140M -117M -509 000 10M -17M -23M -148M -19M -123M -38M
otherNonCashItems 151M 35M 262M 30M 114M 124M 215M 59M 24M 28M 309M 137M 174M 96M
netCashProvidedByOperatingActivities 325M 154M -8M 44M 124M -82M 104M 359M -59M -166M -541M -115M -642M -615M
investmentsInPropertyPlantAndEquipment -12M -14M -34M -4M -8M -13M -62M -17M -16M -14M -72M -17M -76M -70M
acquisitionsNet 0 0 0 0 0 0 0 -11M 0 -49M 0 0 0 0
purchasesOfInvestments -210M -469M -1 712M -450M -316M -460M -1 824M -421M -377M -436M -1 977M -157M -1 656M -2 026M
salesMaturitiesOfInvestments 723M 332M 1 572M 424M 358M 405M 1 554M 432M 384M 373M 2 232M 493M 1 464M 1 692M
otherInvestingActivites -450 000 9M 0 42M 40M 6M 0 49M -5M
netCashUsedForInvestingActivites 501M -141M -30M 34M -68M -11M -9M -76M 314M
debtRepayment -494M 0 0 0 0 0 0 0 0
commonStockIssued -131M 81M 108M 133M 26M 25M 0 27M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 176M -27M -5M 131M 3M 8M 53M 19M 297M
netCashUsedProvidedByFinancingActivities -448M 54M 103M 131M 29M 33M 53M 46M 297M
effectOfForexChangesOnCash -927 000 28M -15M 15M -3M -10M 6M -7M -130 000 2M -7M 2M -9M 5M
netChangeInCash 377M 94M 154M 134M 287M -131M -54M 375M -14M -194M 46M 498M 323M -51M
cashAtEndOfPeriod 1 493M 1 116M 969M 1 102M 968M 682M 815M 1 035M 660M 674M 869M 1 075M 822M 499M
cashAtBeginningOfPeriod 1 116M 1 022M 815M 968M 682M 813M 869M 660M 674M 869M 822M 578M 499M 550M
operatingCashFlow 325M 154M -8M 44M 124M -82M 104M 359M -59M -166M -541M -115M -642M -615M
capitalExpenditure -12M -14M -34M -4M -8M -13M -62M -17M -16M -14M -72M -17M -76M -70M
freeCashFlow 313M 139M -43M 40M 116M -94M 42M 342M -75M -180M -613M -132M -718M -685M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-23 2022-02-10 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 58M -4M -13M -4M -31M
netCashProvidedByInvestingActivities -117M -336M 169M -273M -436M
netDebtIssuance 0 0 254M 500M 200M
longTermNetDebtIssuance 0 0 254M 500M 200M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 303M 147M 259M 246M 99M
netCommonStockIssuance 303M 147M 259M 246M 99M
commonStockIssuance 303M 147M 259M 246M 99M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -9M 25M -88M 501M 695M
netCashProvidedByFinancingActivities 294M 172M 426M 1 247M 995M
incomeTaxesPaid 14M 0 0 0 0
interestPaid 68M 0 0 0 0

Earning call transcript

2025 q3
2025-10-30 ET (fiscal 2025 q3)
2025 q2
2025-07-31 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-13 ET (fiscal 2024 q4)
2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2026-02-12 08:12 ET
Alnylam Pharmaceuticals published news for 2025 q4
SEC form 8
2026-02-12 08:05 ET
Alnylam Pharmaceuticals reported for 2025 q4
SEC form 8
2026-02-12 08:05 ET
Alnylam Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-12 12:30 ET
Alnylam Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-12 12:30 ET
Alnylam Pharmaceuticals published news for 2025 q4
SEC form 8
2025-12-11 07:25 ET
Alnylam Pharmaceuticals published news for 2025 q3
SEC form 8
2025-12-11 07:25 ET
Alnylam Pharmaceuticals published news for 2025 q3
SEC form 10
2025-10-30 12:16 ET
Alnylam Pharmaceuticals reported for 2025 q3
SEC form 8
2025-10-30 12:06 ET
Alnylam Pharmaceuticals published news for 2025 q3
SEC form 8
2025-10-30 12:06 ET
Alnylam Pharmaceuticals reported for 2025 q3
SEC form 8
2025-09-10 11:30 ET
Alnylam Pharmaceuticals published news for 2025 q2
SEC form 8
2025-09-10 11:30 ET
Alnylam Pharmaceuticals published news for 2025 q2
SEC form 8
2025-09-10 11:30 ET
Alnylam Pharmaceuticals published news for 2025 q2
SEC form 10
2025-07-31 12:11 ET
Alnylam Pharmaceuticals reported for 2025 q2
SEC form 8
2025-07-31 12:05 ET
Alnylam Pharmaceuticals reported for 2025 q2
SEC form 8
2025-07-31 12:05 ET
Alnylam Pharmaceuticals published news for 2025 q2
SEC form 10
2025-05-01 12:15 ET
Alnylam Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Alnylam Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-13 13:31 ET
Alnylam Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-13 00:00 ET
Alnylam Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Alnylam Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Alnylam Pharmaceuticals published news for 2024 q4
SEC form 10
2024-10-31 08:22 ET
Alnylam Pharmaceuticals reported for 2024 q3
SEC form 10
2024-10-31 00:00 ET
Alnylam Pharmaceuticals reported for 2024 q3
SEC form 10
2024-08-01 08:22 ET
Alnylam Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Alnylam Pharmaceuticals reported for 2024 q2
SEC form 10
2024-05-02 08:21 ET
Alnylam Pharmaceuticals published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Alnylam Pharmaceuticals published news for 2024 q1
SEC form 10
2024-02-15 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Alnylam Pharmaceuticals reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-02 08:22 ET
Alnylam Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-02 08:10 ET
Alnylam Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q3
SEC form 10
2023-08-03 08:18 ET
Alnylam Pharmaceuticals reported for 2023 q2
SEC form 6
2023-08-03 08:10 ET
Alnylam Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-26 17:15 ET
Alnylam Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-30 09:03 ET
Alnylam Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q1
SEC form 8
2023-02-23 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Alnylam Pharmaceuticals published news for 2022 q4
SEC form 10
2022-10-27 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q3
SEC form 8
2022-07-28 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q2
SEC form 10
2022-07-28 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q2
SEC form 8
2022-04-28 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q1
SEC form 10
2022-04-28 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q1
SEC form 8
2022-02-10 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-10 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q4
SEC form 8
2021-10-28 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q3
SEC form 8
2021-08-03 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q2
SEC form 8
2021-04-29 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q1
SEC form 10
2021-04-29 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q1